Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β2-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma
| Autor: | Melvyn R. Danzig, Paul Stryszak, William E. Berger, Carlos E. Baena-Cagnani, Sandra E. Gurné, Lawrence M. DuBuske, Richard R. Lorber |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Leukotriene
Desloratadine business.industry medicine.medical_treatment fungi Immunology General Medicine Histamine H1 Antagonists medicine.disease respiratory tract diseases law.invention body regions Randomized controlled trial law medicine Immunology and Allergy Antihistamine In patient skin and connective tissue diseases business Montelukast medicine.drug Asthma |
| Zdroj: | International Archives of Allergy and Immunology. 130:307-313 |
| ISSN: | 1423-0097 1018-2438 |
| DOI: | 10.1159/000070218 |
| Popis: | Background: Asthma and seasonal allergic rhinitis (SAR) are recognized as manifestations of a single airway disease. Desloratadine has demonstrated efficacy in treating SAR symptoms, including nasal obstruction. Methods: Safety and efficacy of desloratadine and montelukast each were assessed in a double-blind, placebo-controlled trial of patients with SAR and symptoms of asthma, who were assigned randomly to once-daily treatment with desloratadine 5 mg, montelukast 10 mg, or placebo for 4 weeks. Change from baseline of AM/PM reflective total asthma symptom severity scores (TASS), FEV1, individual asthma symptom scores, and β2-agonist usage were assessed. Results: Desloratadine and montelukast each were associated with statistically significant reductions from baseline in the mean TASS averaged over the 4-week period (p ≤0.022 vs. placebo). Individual asthma symptom scores also improved significantly for both therapies (p ≤ 0.05). Patients treated with desloratadine or montelukast demonstrated improvement from baseline in FEV1 versus placebo; significant improvement was seen in a subset of patients with baseline FEV1 2-agonist use (both p < 0.01). Improvements for both therapies were comparable for all efficacy parameters; they were tolerated well with adverse event profiles similar to placebo. Conclusions: Asthma symptoms and β2-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily. Both therapies significantly improved FEV1 in a subset of patients with FEV1 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|